| | | | | | | | | | | | | | | | |
| |
| Issue Date FY: 2024 ( Subtotal = $17,148,817 ) (Continued on the next page) |
| 2024 | 2024 | THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC. | 6720A ROCKLEDGE DR | BETHESDA | MD | 20817-1891 | MONTGOMERY | USA | R01AI174908 | A new strategy to eliminate HIV-1-infected cells by unlocking the Env trimer | 000 | 2 | NIH | 7/25/2024 | $654,702 |
| 2024 | 2024 | THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC. | 6720A ROCKLEDGE DR | BETHESDA | MD | 20817-1891 | MONTGOMERY | USA | R01AI177698 | Maturation of human humoral immunity through repeat malaria challenges | 000 | 2 | NIH | 4/5/2024 | $788,047 |
| 2024 | 2024 | THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC. | 6720A ROCKLEDGE DR | BETHESDA | MD | 20817-1891 | MONTGOMERY | USA | R01AI168295 | Mechanistic elucidation of pathogenic CBM complex mutations associated with atopic disease | 001 | 2 | NIH | 6/17/2024 | $708,492 |
| 2024 | 2024 | THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC. | 6720A ROCKLEDGE DR | BETHESDA | MD | 20817-1891 | MONTGOMERY | USA | R21MH132136 | Intrinsic CRF signaling within the lateral habenula | 001 | 2 | NIH | 8/14/2024 | $18,983 |
| 2024 | 2024 | THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC. | 6720A ROCKLEDGE DR | BETHESDA | MD | 20817-1891 | MONTGOMERY | USA | R21MH132136 | Intrinsic CRF signaling within the lateral habenula | 000 | 2 | NIH | 2/27/2024 | $170,845 |
| 2024 | 2024 | THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC. | 6720A ROCKLEDGE DR | BETHESDA | MD | 20817-1891 | MONTGOMERY | USA | U01AI170033 | Mitigation of Radiation Induced Immune Dysfunction by PrC-210 Treatment | 000 | 3 | NIH | 5/8/2024 | $476,834 |
| 2024 | 2024 | THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC. | 6720A ROCKLEDGE DR | BETHESDA | MD | 20817-1891 | MONTGOMERY | USA | R00NS112612 | The Mechanisms and Functional Consequences of Interhemispheric Plasticity | 000 | 4 | NIH | 6/25/2024 | $241,530 |
| 2024 | 2024 | THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC. | 6720A ROCKLEDGE DR | BETHESDA | MD | 20817-1891 | MONTGOMERY | USA | R21AR081008 | Does joint lavage reduce intraarticular inflammation in high-energy tibial pilon fractures? | 000 | 3 | NIH | 7/19/2024 | $153,232 |
| 2024 | 2024 | THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC. | 6720A ROCKLEDGE DR | BETHESDA | MD | 20817-1891 | MONTGOMERY | USA | R01GM114173 | Evolution of Homologous Recombination Mechanisms | 002 | 8 | NIH | 7/24/2024 | $31,021 |
| 2024 | 2024 | THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC. | 6720A ROCKLEDGE DR | BETHESDA | MD | 20817-1891 | MONTGOMERY | USA | R01GM114173 | Evolution of Homologous Recombination Mechanisms | 001 | 8 | NIH | 5/31/2024 | $65,582 |
| 2024 | 2024 | THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC. | 6720A ROCKLEDGE DR | BETHESDA | MD | 20817-1891 | MONTGOMERY | USA | R01GM114173 | Evolution of Homologous Recombination Mechanisms | 000 | 8 | NIH | 2/16/2024 | $279,194 |
| 2024 | 2024 | THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC. | 6720A ROCKLEDGE DR | BETHESDA | MD | 20817-1891 | MONTGOMERY | USA | R35GM140792 | Regulation of cytoplasmic dynein in vivo | 000 | 4 | NIH | 8/15/2024 | $381,240 |
| 2024 | 2024 | THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC. | 6720A ROCKLEDGE DR | BETHESDA | MD | 20817-1891 | MONTGOMERY | USA | R01AI155983 | Evaluation of Antibody Responses Elicited by Zika Vaccination in Flavivirus-naïve and -experienced Individuals | 002 | 4 | NIH | 5/24/2024 | $82,571 |
| 2024 | 2024 | THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC. | 6720A ROCKLEDGE DR | BETHESDA | MD | 20817-1891 | MONTGOMERY | USA | R01AI155983 | Evaluation of Antibody Responses Elicited by Zika Vaccination in Flavivirus-naïve and -experienced Individuals | 001 | 4 | NIH | 2/28/2024 | $743,136 |
| 2024 | 2024 | THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC. | 6720A ROCKLEDGE DR | BETHESDA | MD | 20817-1891 | MONTGOMERY | USA | R01AA030041 | Leveraging genetic and electronic health record data to identify novel targets and drugs for treating alcohol use disorder | 002 | 3 | NIH | 7/12/2024 | -$8,339 |
| 2024 | 2024 | THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC. | 6720A ROCKLEDGE DR | BETHESDA | MD | 20817-1891 | MONTGOMERY | USA | R01AA030041 | Leveraging genetic and electronic health record data to identify novel targets and drugs for treating alcohol use disorder | 000 | 3 | NIH | 6/10/2024 | $553,007 |
| 2024 | 2024 | THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC. | 6720A ROCKLEDGE DR | BETHESDA | MD | 20817-1891 | MONTGOMERY | USA | R35GM138202 | Cellular organization, division, and differentiation in an ancient, genetically reduced bacterium | 000 | 5 | NIH | 5/9/2024 | $341,175 |
| 2024 | 2024 | THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC. | 6720A ROCKLEDGE DR | BETHESDA | MD | 20817-1891 | MONTGOMERY | USA | U01AI135941 | Targeting HIV reservoirs in children with HIVIS DNA and MVA-CMDR vaccines | 005 | 7 | NIH | 8/14/2024 | $0 |
| 2024 | 2024 | THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC. | 6720A ROCKLEDGE DR | BETHESDA | MD | 20817-1891 | MONTGOMERY | USA | U01AI135941 | Targeting HIV reservoirs in children with HIVIS DNA and MVA-CMDR vaccines | 001 | 7 | NIH | 5/17/2024 | $85,554 |
| 2024 | 2024 | THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC. | 6720A ROCKLEDGE DR | BETHESDA | MD | 20817-1891 | MONTGOMERY | USA | U01AI135941 | Targeting HIV reservoirs in children with HIVIS DNA and MVA-CMDR vaccines | 000 | 7 | NIH | 3/26/2024 | $898,170 |
| 2024 | 2024 | THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC. | 6720A ROCKLEDGE DR | BETHESDA | MD | 20817-1891 | MONTGOMERY | USA | R01GM117155 | Regulation of microtubule organizing centers during mammalian gametogenesis | 001 | 10 | NIH | 6/25/2024 | $34,206 |
| 2024 | 2024 | THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC. | 6720A ROCKLEDGE DR | BETHESDA | MD | 20817-1891 | MONTGOMERY | USA | R01GM117155 | Regulation of microtubule organizing centers during mammalian gametogenesis | 000 | 10 | NIH | 12/4/2023 | $307,860 |
| 2024 | 2024 | THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC. | 6720A ROCKLEDGE DR | BETHESDA | MD | 20817-1891 | MONTGOMERY | USA | U01OH012485 | Grief and health-related quality of life in WTCHR Survivors: Associations with bereavement, trauma exposures, and mental and physical health conditions | 00 | 3 | CDC | 4/2/2024 | $499,343 |
| 2024 | 2024 | THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC. | 6720A ROCKLEDGE DR | BETHESDA | MD | 20817-1891 | MONTGOMERY | USA | R01CA255232 | Isoform-specific signaling as a determinant of RAS-driven oncogenesis | 000 | 3 | NIH | 1/25/2024 | $313,951 |
| 2024 | 2024 | THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC. | 6720A ROCKLEDGE DR | BETHESDA | MD | 20817-1891 | MONTGOMERY | USA | R21CA267515 | Preventing Therapeutic Resistance in RAS-mutated Pediatric Cancers | 000 | 3 | NIH | 1/16/2024 | $164,671 |
| 2024 | 2024 | THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC. | 6720A ROCKLEDGE DR | BETHESDA | MD | 20817-1891 | MONTGOMERY | USA | R01CA255232 | Isoform-specific signaling as a determinant of RAS-driven oncogenesis | 001 | 3 | NIH | 4/16/2024 | $17,443 |
| 2024 | 2024 | THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC. | 6720A ROCKLEDGE DR | BETHESDA | MD | 20817-1891 | MONTGOMERY | USA | R01MH130197 | Impact of IL-15 immunotherapy on tissue-specific CD8 T cells to reduce the CNS HIV reservoir seeding and persistence | 002 | 3 | NIH | 6/25/2024 | $403,931 |
| 2024 | 2024 | THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC. | 6720A ROCKLEDGE DR | BETHESDA | MD | 20817-1891 | MONTGOMERY | USA | R01MH130197 | Impact of IL-15 immunotherapy on tissue-specific CD8 T cells to reduce the CNS HIV reservoir seeding and persistence | 002 | 3 | NIH | 6/25/2024 | $571,837 |
| 2024 | 2024 | THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC. | 6720A ROCKLEDGE DR | BETHESDA | MD | 20817-1891 | MONTGOMERY | USA | U01NS123252 | Antiglutamatergic Therapy to Protect the Brain Against Nerve Agents | 000 | 3 | NIH | 8/21/2024 | $735,815 |
| 2024 | 2024 | THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC. | 6720A ROCKLEDGE DR | BETHESDA | MD | 20817-1891 | MONTGOMERY | USA | R21OD034471 | Identifying the radioprotective potential of radiation-resistant fungi using Drosophila | 000 | 1 | NIH | 7/25/2024 | $239,363 |
| 2024 | 2024 | THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC. | 6720A ROCKLEDGE DR | BETHESDA | MD | 20817-1891 | MONTGOMERY | USA | R01HL167048 | COVID-19 airway inflammation is due to Spike inhibition of CFTR signaling | 001 | 2 | NIH | 6/14/2024 | $46,916 |
| 2024 | 2024 | THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC. | 6720A ROCKLEDGE DR | BETHESDA | MD | 20817-1891 | MONTGOMERY | USA | R01HL167048 | COVID-19 airway inflammation is due to Spike inhibition of CFTR signaling | 000 | 2 | NIH | 12/22/2023 | $527,792 |
| 2024 | 2024 | THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC. | 6720A ROCKLEDGE DR | BETHESDA | MD | 20817-1891 | MONTGOMERY | USA | R21AI174937 | QALYs, Comorbidities, and Cost-effectiveness of HIV Care in the Department of Defense vs the Veterans Health Administration | 000 | 1 | NIH | 8/1/2024 | $156,251 |
| 2024 | 2024 | THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC. | 6720A ROCKLEDGE DR | BETHESDA | MD | 20817-1891 | MONTGOMERY | USA | R03HD114176 | Quantifying Locomotor Outcomes with Agonist-Antagonist Myoneural Interface | 001 | 1 | NIH | 9/25/2024 | $0 |
| 2024 | 2024 | THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC. | 6720A ROCKLEDGE DR | BETHESDA | MD | 20817-1891 | MONTGOMERY | USA | R03HD114176 | Quantifying Locomotor Outcomes with Agonist-Antagonist Myoneural Interface | 000 | 1 | NIH | 7/26/2024 | $240,722 |
| 2024 | 2024 | THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC. | 6720A ROCKLEDGE DR | BETHESDA | MD | 20817-1891 | MONTGOMERY | USA | R21DC021516 | Improving Interpretation of Hearing- Related Patient Reported Outcomes for Bilingual Adults | 000 | 1 | NIH | 7/22/2024 | $150,617 |
| 2024 | 2024 | THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC. | 6720A ROCKLEDGE DR | BETHESDA | MD | 20817-1891 | MONTGOMERY | USA | R21NS136126 | Inflammation and white matter microstructural alterations after OP exposure | 001 | 1 | NIH | 9/16/2024 | $0 |
| 2024 | 2024 | THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC. | 6720A ROCKLEDGE DR | BETHESDA | MD | 20817-1891 | MONTGOMERY | USA | R21NS136126 | Inflammation and white matter microstructural alterations after OP exposure | 000 | 1 | NIH | 8/1/2024 | $254,408 |
| 2024 | 2024 | THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC. | 6720A ROCKLEDGE DR | BETHESDA | MD | 20817-1891 | MONTGOMERY | USA | UM1AI108568 | United States Military HIV Research Program (MHRP) Clinical Trials Unit | 003 | 11 | NIH | 6/20/2024 | $134,429 |
| 2024 | 2024 | THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC. | 6720A ROCKLEDGE DR | BETHESDA | MD | 20817-1891 | MONTGOMERY | USA | UM1AI108568 | United States Military HIV Research Program (MHRP) Clinical Trials Unit | 003 | 11 | NIH | 6/20/2024 | $639,501 |
| 2024 | 2024 | THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC. | 6720A ROCKLEDGE DR | BETHESDA | MD | 20817-1891 | MONTGOMERY | USA | UM1AI108568 | United States Military HIV Research Program (MHRP) Clinical Trials Unit | 004 | 11 | NIH | 7/2/2024 | $114,285 |
| 2024 | 2024 | THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC. | 6720A ROCKLEDGE DR | BETHESDA | MD | 20817-1891 | MONTGOMERY | USA | UM1AI108568 | United States Military HIV Research Program (MHRP) Clinical Trials Unit | 002 | 11 | NIH | 11/2/2023 | $134,429 |
| 2024 | 2024 | THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC. | 6720A ROCKLEDGE DR | BETHESDA | MD | 20817-1891 | MONTGOMERY | USA | UM1AI108568 | United States Military HIV Research Program (MHRP) Clinical Trials Unit | 002 | 11 | NIH | 11/2/2023 | $639,502 |
| 2024 | 2024 | THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC. | 6720A ROCKLEDGE DR | BETHESDA | MD | 20817-1891 | MONTGOMERY | USA | R35GM139619 | Temporal and Metabolic Regulation of Restimulation-Induced Cell Death (RICD) in Human T Cells | 001 | 4 | NIH | 5/20/2024 | $38,123 |
| 2024 | 2024 | THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC. | 6720A ROCKLEDGE DR | BETHESDA | MD | 20817-1891 | MONTGOMERY | USA | R35GM139619 | Temporal and Metabolic Regulation of Restimulation-Induced Cell Death (RICD) in Human T Cells | 000 | 4 | NIH | 12/11/2023 | $343,117 |
| 2024 | 2024 | THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC. | 6720A ROCKLEDGE DR | BETHESDA | MD | 20817-1891 | MONTGOMERY | USA | R21AI173635 | HTLV-1 Replication/Reactivation-Induced DNA Damage: Mechanisms and Pathogenesis | 002 | 2 | NIH | 5/10/2024 | $18,983 |
| 2024 | 2024 | THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC. | 6720A ROCKLEDGE DR | BETHESDA | MD | 20817-1891 | MONTGOMERY | USA | R21AI173635 | HTLV-1 Replication/Reactivation-Induced DNA Damage: Mechanisms and Pathogenesis | 000 | 2 | NIH | 10/24/2023 | $170,845 |
| 2024 | 2024 | THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC. | 6720A ROCKLEDGE DR | BETHESDA | MD | 20817-1891 | MONTGOMERY | USA | R21AI173635 | HTLV-1 Replication/Reactivation-Induced DNA Damage: Mechanisms and Pathogenesis | 001 | 2 | NIH | 11/27/2023 | $0 |
| 2024 | 2024 | THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC. | 6720A ROCKLEDGE DR | BETHESDA | MD | 20817-1891 | MONTGOMERY | USA | R00HD099520 | Molecular analysis of MEHMO syndrome mutations in translation factor eIF2 | 001 | 4 | NIH | 5/6/2024 | $22,051 |
|